Literature DB >> 1901775

The spot test is not a reliable screening procedure for mucopolysaccharidoses.

J G de Jong1, J J Hasselman, A A van Landeghem, H L Vader, R A Wevers.   

Abstract

To check the reliability of the Ames MPS paper spot test, which is based on the Azure A dye, we sent a series of urine samples to three laboratories where the spot test is part of the metabolic screening for mucopolysaccharidoses. In these laboratories false-negative results ranged between 19% and 35% and false-positive results ranged between 12% and 29% of all samples submitted. In contrast, the quantitative dimethylmethylene blue test (Clin Chem 1989;35:1472-7) detected an increased glycosaminoglycan content in all urine samples from mucopolysaccharidosis patients and gave no false-positive results. In the latter procedure, glycosaminoglycan content is expressed per millimole of creatinine, and age-dependent reference values are used. We conclude that the Ames spot test and other spot tests are unreliable as a screening procedure for mucopolysaccharidoses and should not be used to screen for these diseases.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1901775

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  15 in total

1.  Reliability of a visual test for the rapid detection of mucopolysaccharidoses: GAG-test(®).

Authors:  Sergio Lage; José A Prieto; Fernando Andrade; Amaia Sojo; Pablo Sanjurjo; Luis J Aldámiz-Echevarría
Journal:  J Clin Lab Anal       Date:  2011       Impact factor: 2.352

2.  Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidoses and mucolipidoses.

Authors:  Francyne Kubaski; Yasuyuki Suzuki; Kenji Orii; Roberto Giugliani; Heather J Church; Robert W Mason; Vũ Chí Dũng; Can Thi Bich Ngoc; Seiji Yamaguchi; Hironori Kobayashi; Katta M Girisha; Toshiyuki Fukao; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2016-12-22       Impact factor: 4.797

Review 3.  Glycosaminoglycans detection methods: Applications of mass spectrometry.

Authors:  Francyne Kubaski; Harumi Osago; Robert W Mason; Seiji Yamaguchi; Hironori Kobayashi; Mikako Tsuchiya; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2016-09-28       Impact factor: 4.797

Review 4.  Newborn screening of mucopolysaccharidoses: past, present, and future.

Authors:  Nivethitha Arunkumar; Thomas J Langan; Molly Stapleton; Francyne Kubaski; Robert W Mason; Rajendra Singh; Hironori Kobayashi; Seiji Yamaguchi; Yasuyuki Suzuki; Kenji Orii; Tadao Orii; Toshiyuki Fukao; Shunji Tomatsu
Journal:  J Hum Genet       Date:  2020-04-10       Impact factor: 3.172

Review 5.  Newborn screening and diagnosis of mucopolysaccharidoses.

Authors:  Shunji Tomatsu; Tadashi Fujii; Masaru Fukushi; Toshihiro Oguma; Tsutomu Shimada; Miho Maeda; Kazuhiro Kida; Yuniko Shibata; Hideyuki Futatsumori; Adriana M Montaño; Robert W Mason; Seiji Yamaguchi; Yasuyuki Suzuki; Tadao Orii
Journal:  Mol Genet Metab       Date:  2013-06-21       Impact factor: 4.797

6.  MPS screening methods, the Berry spot and acid turbidity tests, cause a high incidence of false-negative results in sanfilippo and morquio syndromes.

Authors:  Chang Chih-Kuang; Lin Shuan-Pei; Lee Shyue-Jye; Wang Tuen-Jen
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

7.  Glycosaminoglycans analysis in blood and urine of patients with mucopolysaccharidosis.

Authors:  Shaukat A Khan; Robert W Mason; Roberto Giugliani; Kenji Orii; Toshiyuki Fukao; Yasuyuki Suzuki; Seiji Yamaguchi; Hironori Kobayashi; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2018-05-17       Impact factor: 4.797

8.  Group tests for selective screening of inborn errors of metabolism.

Authors:  M Duran; L Dorland; S K Wadman; R Berger
Journal:  Eur J Pediatr       Date:  1994       Impact factor: 3.183

9.  Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfalls.

Authors:  Barbara K Burton; Roberto Giugliani
Journal:  Eur J Pediatr       Date:  2012-03-01       Impact factor: 3.183

10.  Presentation and Treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome).

Authors:  Molly Stapleton; Francyne Kubaski; Robert W Mason; Hiromasa Yabe; Yasuyuki Suzuki; Kenji E Orii; Tadao Orii; Shunji Tomatsu
Journal:  Expert Opin Orphan Drugs       Date:  2017-03-08       Impact factor: 0.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.